Unknown

Dataset Information

0

Combining anti-IL-7R? antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes.


ABSTRACT: Autoantigen-specific methods to prevent and treat Type 1 Diabetes (T1D) carry high hopes to permanently cure this disease, but have largely failed in clinical trials. One suggested approach to increase the efficacy of islet antigen-specific vaccination is to combine it with a modulator of the T cell response, with the goal of reducing effector differentiation and promoting regulatory T cells (Tregs). Here we asked if addition of antibodies that block the IL-7/IL-7R? pathway altered the T cell response to islet antigen vaccination and prevented T1D in non-obese diabetic (NOD) mice. Anti-IL-7R? monoclonal antibodies (mAbs) reduced the numbers of islet antigen-specific T cells generated after vaccination with islet peptides and alum. However, addition of anti-IL-7R? antibodies to peptide/alum vaccination unexpectedly increased non-specific IFN-?, IL-2 and IL-10 cytokine production and did not result in improved prevention of T1D onset. In a second approach, we used a conjugate vaccine to deliver islet autoantigens, using Keyhole Limpet Hemocyanin (KLH) as a carrier. Islet antigen-KLH vaccination led to a significant expansion of antigen-specific Tregs and delayed diabetes onset in NOD mice. These outcomes were not further improved by addition of anti-IL-7R? antibodies. To the contrary, blocking IL-7R? during vaccination led to non-specific cytokine production and reduced the efficacy of a KLH-conjugated vaccine to prevent T1D. Our study thus revealed that adding anti-IL-7R? antibodies during autoantigen immunization did not improve the efficacy of such vaccinations to prevent T1D, despite altering some aspects of the T cell response in a potentially advantageous way. Further refinement of this approach will be required to separate the beneficial from the adverse effects of anti-IL-7R? antibodies to treat autoimmune disease.

SUBMITTER: Vazquez-Mateo C 

PROVIDER: S-EPMC6433345 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combining anti-IL-7Rα antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes.

Vazquez-Mateo Cristina C   Collins Justin J   Goldberg Sarah J SJ   Lawson Maxx M   Hernandez-Escalante Jaileene J   Dooms Hans H  

PloS one 20190325 3


Autoantigen-specific methods to prevent and treat Type 1 Diabetes (T1D) carry high hopes to permanently cure this disease, but have largely failed in clinical trials. One suggested approach to increase the efficacy of islet antigen-specific vaccination is to combine it with a modulator of the T cell response, with the goal of reducing effector differentiation and promoting regulatory T cells (Tregs). Here we asked if addition of antibodies that block the IL-7/IL-7Rα pathway altered the T cell re  ...[more]

Similar Datasets

2022-12-12 | GSE218777 | GEO
| S-EPMC7424196 | biostudies-literature
| S-EPMC4965903 | biostudies-literature
| S-EPMC10619440 | biostudies-literature
| PRJNA905436 | ENA
| S-EPMC8462360 | biostudies-literature
| S-EPMC6958162 | biostudies-literature
| S-EPMC4922493 | biostudies-literature
| S-EPMC2860016 | biostudies-literature
| S-EPMC6387412 | biostudies-literature